DanDrit® Biotech A/S is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. DanDrit was founded in 2001 on the research of Professor Jesper Zeuthen at the Danish Cancer Society (Kraeftens Bekaempelse). Dendritic cells are a critical component of the immune system. The ability of dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit. Our expertise in producing dendritic cells from patient blood is combined with conventional production methods to make new and advanced vaccines for cancer patients.
The proprietary technology upon which MCV is based is protected by several issued patents.
DanDrit Corporation Pte Ltd at the National Cancer Center in Singapore is a 100% owned subsidiary of DanDrit Biotech A/S.